Industry Landscape

Globally, Indian pharma has contributed to improve public health outcomes. India accounts for 60% of global vaccine production, contributing 40 to 70% of the WHO demand for Diphtheria, Tetanus and Pertussis (DPT) and Bacillus Calmette–Guérin (BCG) vaccines, and 90% of the WHO demand for the measles vaccine. Estimates suggest that one in every three pills consumed in the United States is produced by an Indian generics manufacturer. In the UK, approximately 25% of the medicines used are made in India.

Why this Forum

The 9th Edition Global Pharma Regulatory Summit organized by CPhI Conferences will witness a gathering of senior leaders and experts of regulatory affairs, compliances, quality assurance and policy makers to discuss and share their perspectives on current trends and challenges in global regulatory landscape. The themes are designed to inspire and enable the brilliant minds from across the pharma ecosystem to come together to examine, discuss and debate how to improve regulatory system and lower the challenges associated

Who Should Attend?

The 9th Global Pharma Regulatory Summit will bring together leading Regulatory experts and decision makers from across the pharma industry. These delegates will be attending this summit to learn about the latest updates on regulations, best practice and compliance advances in the sector and much more.


VP’s; Directors; HODs
Sr. Managers / General Managers
Managers/ Deputy Managers

Programme Focus

Why Attend

Access the latest information and insights on global regulatory affairs program
Analyze how stakeholders around the world are supporting regulatory system optimization
Examine the
impact of new initiatives for emerging markets
Network with innovators and opinion leaders in the pharma regulatory affairs arena

Glimpses & Testimonials


Full speaker list

Download Brochure


Full speaker list • Full conference agenda

Download Brochure